PV Reporter and MPN Cancer Connection founder David Wallace is interviewed on “PV Pod: Stories from the Marrow.” In the newly released podcast, we shed light on MPN self-advocacy and education on myeloproliferative neoplasms. Helpful tips from the podcast: “It’s normal to be depressed and angry about the situation. I think seeking help is very […]
Observational Study Reveals Differences between Aquagenic and Non-aquagenic Itching in MPNs
Abstract Background Pruritus is a frequent symptom experienced by patients with myeloproliferative neoplasms (MPN). Aquagenic pruritus (AP) is the most common type. The Myeloproliferative Neoplasm-Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) self-report questionnaires were distributed to MPN patients before consultations. Objectives The aim of this study was to assess clinical incidence (phenotypical evolution and […]
MPN’s and Alzheimer’s: Is there a connection?
by David Wallace and Lou Ann Donovan Chronic inflammation is increasingly understood as a significant factor in the progression of many diseases, including Alzheimer’s and myeloproliferative neoplasms (MPNs), a group of blood cancers[1][2]. Myeloid blood cells, which are overproduced in MPNs, have been associated with Alzheimer’s disease, suggesting a link between these conditions[3]. Emerging evidence […]
9 Tips for Reducing Risks of Thrombosis in MPNs
by David Wallace Understanding Thrombosis in MPN Patients Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers that affect the normal functioning of blood cells. People living with MPNs, such as polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), have an increased risk of developing blood clots, or thrombosis. Thrombosis can lead to […]
Dr. Srdan Verstovsek Joins Kartos Therapeutics as CMO
World-Renowned Physician-Scientist and Global Expert in Myeloproliferative Neoplasms Will Be Instrumental in Advancing the Development of Navtemadlin and Other Innovative Therapies to Improve the Lives of Cancer Patients REDWOOD CITY, Calif., March 02, 2023–(BUSINESS WIRE)–Kartos Therapeutics, Inc. (“Kartos” or the “Company”), a clinical stage biopharmaceutical company dedicated to the development of novel, targeted therapeutics that […]
- 1
- 2
- 3
- …
- 8
- Next Page »
